Related Experiment Video
Updated: Apr 15, 2026

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro
Published on: June 16, 2022
Psychosine inhibits osteoclastogenesis and bone resorption via G protein-coupled receptor 65
1Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Poongnap-2Dong, Songpa-Gu, Seoul, 138-736, South Korea.
Background:
It was recently reported that G protein-coupled receptor 65 (GPR65) suppresses ovariectomy-induced bone loss.
Aim:
The present study investigated the role of the lysosphingolipid psychosine, a GPR65 ligand, on osteoclastic differentiation and bone resorption.
Methods:
Osteoclasts were differentiated from mouse bone marrow macrophages. Tartrate-resistant acid phosphatase-positive multinucleated cells were considered to be osteoclasts, and the resorption area was measured by incubating the cells on dentine discs. The expression levels of osteoclast differentiation markers were assessed by qRT-PCR. GPR65 siRNA and its scrambled siRNA were transfected with lipofectamine. Intracellular cyclic adenosine monophosphate (cAMP) levels were assessed using a direct enzyme immunoassay.
Results:
Psychosine inhibited osteoclastogenesis and in vitro bone resorption without any significant effect on the viability of pre-osteoclasts, decreased the expression of osteoclast differentiation markers significantly, and increased intracellular cAMP levels. The knockdown of GPR65 by its siRNA restored osteoclastogenesis and decreased cAMP levels in the presence of psychosine.
Conclusion:
Psychosine inhibits osteoclastogenesis by increasing intracellular cAMP levels via GPR65.
Insights
The lysosphingolipid psychosine inhibits bone loss by suppressing osteoclast formation and activity via G protein-coupled receptor 65 (GPR65). This mechanism involves increased intracellular cyclic adenosine monophosphate (cAMP) levels.
Area of Science:
- Bone biology
- Endocrinology
- Pharmacology
Background:
- G protein-coupled receptor 65 (GPR65) is implicated in suppressing ovariectomy-induced bone loss.
- Lysosphingolipids are signaling molecules with diverse biological functions.
Purpose of the Study:
- To investigate the effect of psychosine, a GPR65 ligand, on osteoclast differentiation and bone resorption.
- To elucidate the molecular mechanism underlying psychosine's action on bone cells.
Main Methods:
- Osteoclasts were differentiated from mouse bone marrow macrophages.
- In vitro bone resorption was assessed using dentine discs.
- Gene expression of osteoclast markers was analyzed by qRT-PCR.
- GPR65 was knocked down using siRNA.
- Intracellular cyclic adenosine monophosphate (cAMP) levels were measured.
Main Results:
- Psychosine significantly inhibited osteoclastogenesis and in vitro bone resorption.
- Psychosine decreased the expression of osteoclast differentiation markers.
- Psychosine treatment led to increased intracellular cAMP levels.
- GPR65 knockdown abrogated the effects of psychosine on osteoclastogenesis and cAMP levels.
Conclusions:
- Psychosine inhibits osteoclastogenesis and bone resorption.
- The inhibitory effect of psychosine is mediated through GPR65.
- Increased intracellular cAMP levels are a key mechanism in psychosine's action.
Related Concept Videos
Osteoclasts in Bone Remodeling
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Remodeling
GPCR Desensitization
G-protein Coupled Receptors
Skeleton and Calcium Homeostasis

